Clinical trials: Healthy Males
Healthy
A Single and Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of JNJ-42165279 in Healthy Japanese Male Participants
The purpose of this study is to assess the safety, tolerability, and pharmacokinetics of JNJ-42165279 in healthy Japanese male participants after single and multiple oral dose administration.
- Trial name
- NCT03564379
- Testing
- JNJ-42165279
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
IBD
Single Ascending Dose Study to Assess the Safety, Tolerability, PK and PD Effects in Male Volunteers
This will be a double-blind, randomized, placebo-controlled, single ascending dose, Phase I study in healthy male subjects.
- Trial name
- NCT02914262
- Testing
- AKB-4924
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Aerpio Therapeutics
Healthy
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of After Administrations of DWP14012 Alone and Combinations of DWP14012, Clarithromycin and Amoxicillin in Healthy Male Subjects
This is a randomized, open-label, multiple dose, two-part phase I clinical trial to compare the pharmacokinetics, pharmacodynamics and safety/tolerability of DWP14012 after administrations of DWP14012 alone and combinations of…
- Trial name
- NCT03487562
- Testing
- DWP14012 Amg, DWP14012 Bmg, Clarithromycin
- Where
- South Korea
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Healthy
A Study in Healthy People to Compare 3 Different Formulations of Apremilast Tablets Taken With or Without Food
The aim of this trial is to establish bioequivalence between EU-, US- and Japan-sourced Otezla® tablet formulations to assure comparability of results from Phase III trials of BI 730357 (new oral agent for treatment of psoriasis…
- Trial name
- NCT04811573
- Testing
- EU-sourced Otezla®, US-sourced Otezla®, Japan-sourced Otezla®
- Where
- Germany
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy Volunteers, Pharmacodynamics of Mirabegron
A Study in Healthy Young Men to Look at What Drives the Cardiovascular Effects After Dosing With Mirabegron.
To explore what is driving heart-rate increases after dosing with mirabegron. Subjects will be given a beta-blocker at the same time as mirabegron.
- Trial name
- NCT01284868
- Testing
- mirabegron, Bisoprolol, propranolol
- Where
- France
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Inc
Stage, Prostate Cancer
Sulforadex in Healthy Volunteers SAD
To determine the safety and tolerability of single escalating doses of Sulforadex® in healthy male volunteers.
- Trial name
- NCT01948362
- Testing
- Sulforadex, Alpha cyclodextrin
- Where
- United Kingdom
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Evgen Pharma
Healthy Volunteers
Food and Ethnicity Effects on Pharmacokinetics and Safety of JPI-547 in Healthy Male Participants
This study aims to evaluate the effects of food or ethnicity on the pharmacokinetics and safety/tolerability of JPI-547 after a single oral administration in healthy male Korean, Caucasian, and Chinese participants.
- Trial name
- NCT07570186
- Testing
- JPI-547
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Onconic Therapeutics Inc.
Schizophrenia
Study Evaluating the Safety and Tolerability of SCA-136 in Healthy Japanese Male Subjects
This study is being conducted to assess the safety and tolerability of ascending multiple oral doses of SCA-136 administered to healthy Japanese male subjects.
- Trial name
- NCT00505973
- Testing
- SCA-136
- Where
- Japan
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Hypertriglyceridemia
A Phase 1, First Time in Humans Study of NST-1024
A first time in man study of NST-1024
- Trial name
- NCT04630366
- Testing
- NST-1024
- Where
- United Kingdom
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- NorthSea Therapeutics B.V.
Healthy
Open-Label Absorption, Distribution, Metabolism, Excretion (ADME) and Pharmacokinetics (PK) Following a Single Oral Dose of AZD1236 in Healthy Male Subjects
The purpose of this study is to characterise the metabolism, excretion and pharmacokinetics of a single oral dose of [14C] AZD1236 in healthy male subjects.
- Trial name
- NCT01007929
- Testing
- 14C-AZD1236
- Where
- United Kingdom
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
A Study in Healthy Men to Test Whether Four Capsules of 25 mg Nintedanib Are Taken up in the Body in the Same Way as One 100 mg Capsule
The main objective of this trial is to investigate the relative bioavailability of 100 mg nintedanib given as four capsules of 25 mg nintedanib compared with one capsule of 100 mg nintedanib.
- Trial name
- NCT04938453
- Testing
- nintedanib 25 mg, nintedanib 100 mg
- Where
- Germany
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
Relative Bioavailability of Telmisartan and HCTZ in Two Experimental Formulations Compared to the Standard Formulation Telmisartan and HCTZ in Healthy Female and Male Subjects
Study to assess the comparative pharmacokinetics of telmisartan/HCTZ in two new formulations based on sodium salt compared to the present commercial formulation (MicardisPlus®)
- Trial name
- NCT02262572
- Testing
- Telmisartan /HCTZ - compression tablet (DC), Telmisartan /HCTZ - dry granulation tablet (DG), Telmisartan /HCTZ - present commercial formulation
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
Impact of Changing the Dosing Regimen on the PK Profile of ODM-203
This Phase I study in healthy male volunteers will evaluate the impact of the effect of food on the pharmacokinetic profile of ODM-203.
- Trial name
- KIPEV (NCT03240445)
- Testing
- ODM-203 (Period 1), ODM-203 (Period 2), ODM-203 (Periods 3-6)
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Orion Corporation, Orion Pharma
Healthy, Pharmacokinetics of ASP1585
A Study to Assess the Systemic Disposition of ASP1585 After Administration of 14C-labeled Drug
The objective of this study is to assess the systemic disposition of ASP1585 after oral administration of 14C-labeled drug in healthy male subjects.
- Trial name
- NCT01124747
- Testing
- ASP1585, 14C-Labeled ASP1585
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Inc
Healthy
Effect of BIIL 284 BS on the Pharmacokinetics of Theophylline in Healthy Male Volunteers
To evaluate the effect of multiple doses of BIIL 284 BS on the pharmacokinetics of a single dose of theophylline.
- Trial name
- NCT02273440
- Testing
- BIIL 284 BS, Theophylline
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Autosomal Dominant Polycystic Kidney
To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AL01211 in Healthy Volunteers
The study is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of Oral AL01211 in healthy volunteers
- Trial name
- NCT04908462
- Where
- Australia
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- AceLink Therapeutics, Inc.
Nonalcoholic Steatohepatitis (NASH), Primary Sclerosing Cholangitis (PSC)
Subcutaneous Doses of CM-101 as a Treatment for Medical Conditions Involving Inflammatory and Fibrotic Mechanisms in Healthy Male Subjects
CM-101 is developed as treatment for medical conditions involving inflammatory and fibrotic mechanisms such as non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).
- Conditions
- Nonalcoholic Steatohepatitis (NASH), Primary Sclerosing Cholangitis (PSC), Systemic Sclerosis (SSc)
- Trial name
- NCT06037577
- Testing
- CM-101
- Where
- Israel
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- ChemomAb Ltd.
Healthy
A Study to Test How Well Men Tolerate Different Doses of BI 3006337
The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics of BI 3006337 in healthy male subjects following subcutaneous administration of single-rising doses.
- Trial name
- NCT05076422
- Testing
- BI 3006337
- Where
- 2 sites in Belgium, Netherlands
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
Bioequivalence Study of Two Finasteride 5 mg Tablet Formulations Under Non-Fasting Conditions
The objective of this study was to evaluate the relative bioavailability of the test formulation of finasteride 5 mg tablets (Dr.
- Trial name
- NCT01264302
- Testing
- Finasteride
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Dr. Reddy's Laboratories Limited
Dyslipidemia
Evaluation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TA-8995 After Multiple Doses in Healthy Subjects
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of TA-8995 after multiple doses in healthy adult male subjects
- Trial name
- NCT01879020
- Testing
- TA-8995
- Where
- Germany
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Tanabe Pharma Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.